Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,346 shares of the biopharmaceutical company’s stock after selling 18,835 shares during the period. Handelsbanken Fonder AB’s holdings in Alnylam Pharmaceuticals were worth $12,788,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals in the third quarter worth about $29,000. R Squared Ltd bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $33,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC raised its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,356 shares of company stock worth $22,498,551 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALNY. Scotiabank cut their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, February 14th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Finally, Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Stock Down 0.2 %

Alnylam Pharmaceuticals stock opened at $250.59 on Friday. The firm has a fifty day moving average price of $254.14 and a two-hundred day moving average price of $263.03. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market cap of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.